employer coverage glp-1 news october 2025 Among the largest employers (with at least 5,000 workers), 43% now cover GLP -1 weight-loss drugs, up from 28% last year. A majority (59%) of those same employers say their cost for the Health Benefits In 2025: Family
Description
The use of GLP-1RA is a new therapeutic strategy that addresses both metabolic and cognitive/neuropsychiatric aspects, which is fundamentally important for the treatment of comorbid diseases.

They lost 30 lbs

Unless you live under a rock, by now you've heard of semaglutide - the weekly weight loss injection

We review how it works.
Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions

The most important things to know about #GLP1 medications, taken without any needles
